Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists map immune cells in pituitary tumors to unlock new treatments

NCT ID NCT07594262

Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the immune cells inside pituitary tumors to better understand how they behave. Researchers will analyze tumor samples from 60 adults who are having surgery to remove their pituitary tumor. The goal is to find clues that could lead to new immune-based treatments for aggressive pituitary tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with pituitary adenomas

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * indication as per clinical practice and in agreement to current guidelines for surgical removal of the PitNET0; * patient naïve to medical therapy before surgical removal of PitNET; * Diagnosis of PitNET confirmed through the study pathological/histological; * over 18 years of age; * acceptance of participation in the study, by signing an informed consent. Exclusion Criteria: * History of medical therapy with analogs of somatostatin or dopamine agonist, previous the removal of the pituitary adenoma; * history of radiotherapy of the head and neck region earlier than 10 years after resection of the adenoma pituitary; * history of autoimmune diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pituitary tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pituitary Neoplasms pituitary tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pituitary tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC ENDOCRINOLOGIA

    RECRUITING

    Rome, Lazio, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.